O	0	9	Treatment
O	10	12	of
B-condition	13	25	chemotherapy
I-condition	25	26	-
I-condition	26	33	induced
I-condition	34	40	anemia
O	41	43	in
O	44	50	breast
O	51	57	cancer
O	57	58	:
O	59	66	results
O	67	69	of
O	70	71	a
O	72	82	randomized
O	83	93	controlled
O	94	99	trial
O	100	102	of
B-intervention	103	114	darbepoetin
I-intervention	115	119	alfa
O	120	123	200
O	124	130	microg
O	131	136	every
O	137	138	2
O	139	144	weeks
O	145	151	versus
B-control	152	159	epoetin
I-control	160	164	alfa
O	165	167	40
O	167	168	,
O	168	171	000
O	172	173	U
O	174	180	weekly
O	180	181	.

O	182	189	Current
O	190	202	chemotherapy
O	203	211	regimens
O	212	215	for
O	216	222	breast
O	223	229	cancer
O	230	236	result
O	237	239	in
O	240	244	high
O	245	255	incidences
O	256	258	of
O	259	265	anemia
O	265	266	,
O	267	272	which
O	273	276	can
O	277	279	be
O	280	287	treated
O	288	292	with
O	293	307	erythropoietic
O	308	314	agents
O	314	315	.

O	316	319	The
O	320	328	relative
O	329	337	efficacy
O	338	340	of
O	341	352	darbepoetin
O	353	357	alfa
O	358	361	and
O	362	369	epoetin
O	370	374	alfa
O	375	378	was
O	379	387	explored
O	388	390	in
O	391	395	this
O	396	401	phase
O	402	404	II
O	404	405	,
O	406	410	open
O	410	411	-
O	411	416	label
O	416	417	,
O	418	428	randomized
O	428	429	,
O	430	441	multicenter
O	442	447	trial
O	448	450	in
B-eligibility	451	457	anemic
I-eligibility	458	466	patients
I-eligibility	467	471	with
I-eligibility	472	478	breast
I-eligibility	479	485	cancer
I-eligibility	486	495	receiving
I-eligibility	496	508	chemotherapy
O	508	509	.

O	510	518	Patients
O	519	523	were
O	524	534	randomized
O	535	537	at
O	538	539	a
O	540	541	1
O	541	542	:
O	542	543	1
O	544	549	ratio
O	550	552	to
O	553	560	receive
O	561	572	darbepoetin
O	573	577	alfa
O	578	581	200
O	582	588	microg
O	589	594	every
O	595	596	2
O	597	602	weeks
O	603	604	(
O	604	605	n
O	606	607	=
B-intervention-participants	608	610	72
O	610	611	)
O	612	614	or
O	615	622	epoetin
O	623	627	alfa
O	628	630	40
O	630	631	,
O	631	634	000
O	635	636	U
O	637	643	weekly
O	644	645	(
O	645	646	n
O	647	648	=
B-control-participants	649	651	69
O	651	652	)
O	653	656	for
O	657	658	<
O	659	661	or
O	662	663	=
O	664	666	16
O	667	672	weeks
O	672	673	.

B-outcome-Measure	674	682	Clinical
I-outcome-Measure	683	686	and
I-outcome-Measure	687	698	hematologic
O	699	708	endpoints
O	709	712	and
O	713	723	validation
O	724	726	of
O	727	728	a
O	729	734	novel
O	735	742	patient
O	743	755	satisfaction
O	756	769	questionnaire
O	770	773	for
O	774	780	anemia
O	781	790	treatment
O	791	795	were
O	796	805	evaluated
O	806	809	for
O	810	813	all
O	814	822	patients
O	823	833	randomized
O	834	836	to
O	837	844	receive
O	845	846	>
O	847	849	or
O	850	851	=
O	852	853	1
O	854	858	dose
O	859	861	of
O	862	867	study
O	868	872	drug
O	872	873	.

O	874	882	Baseline
O	883	898	characteristics
O	899	903	were
O	904	913	generally
O	914	921	similar
O	922	929	between
O	930	939	treatment
O	940	946	groups
O	946	947	.

B-outcome	948	952	Mean
I-outcome	953	960	changes
I-outcome	961	963	in
I-outcome	964	974	hemoglobin
I-outcome	975	976	(
I-outcome	976	978	Hb
I-outcome	978	979	)
I-outcome	980	985	level
O	986	990	from
O	991	999	baseline
O	1000	1004	were
O	1005	1012	similar
O	1013	1015	at
B-iv-cont-mean	1016	1017	1
I-iv-cont-mean	1017	1018	.
I-iv-cont-mean	1018	1019	9
I-iv-cont-mean	1020	1021	g
I-iv-cont-mean	1021	1022	/
I-iv-cont-mean	1022	1024	dL
O	1025	1028	for
O	1029	1040	darbepoetin
O	1041	1045	alfa
O	1046	1049	and
B-cv-cont-mean	1050	1051	1
I-cv-cont-mean	1051	1052	.
I-cv-cont-mean	1052	1053	7
I-cv-cont-mean	1054	1055	g
I-cv-cont-mean	1055	1056	/
I-cv-cont-mean	1056	1058	dL
O	1059	1062	for
O	1063	1070	epoetin
O	1071	1075	alfa
O	1075	1076	.

B-outcome	1077	1090	Hematopoietic
I-outcome	1091	1100	responses
O	1101	1102	(
O	1102	1103	>
O	1104	1106	or
O	1107	1108	=
O	1109	1110	2
O	1111	1112	g
O	1112	1113	/
O	1113	1115	dL
O	1116	1124	increase
O	1125	1127	in
O	1128	1130	Hb
O	1131	1136	level
O	1137	1141	from
O	1142	1150	baseline
O	1151	1153	or
O	1154	1156	Hb
O	1157	1162	level
O	1163	1164	>
O	1165	1167	or
O	1168	1169	=
O	1170	1172	12
O	1173	1174	g
O	1174	1175	/
O	1175	1177	dL
O	1177	1178	)
O	1179	1183	were
O	1184	1188	also
O	1189	1196	similar
O	1197	1204	between
O	1205	1211	groups
O	1212	1213	(
B-iv-bin-percent	1213	1215	88
I-iv-bin-percent	1215	1216	%
O	1217	1220	for
O	1221	1232	darbepoetin
O	1233	1237	alfa
O	1238	1241	and
B-cv-bin-percent	1242	1244	81
I-cv-bin-percent	1244	1245	%
O	1246	1249	for
O	1250	1257	epoetin
O	1258	1262	alfa
O	1262	1263	)
O	1263	1264	.

O	1265	1268	The
O	1269	1280	proportions
O	1281	1283	of
B-outcome	1284	1292	patients
I-outcome	1293	1296	who
I-outcome	1297	1305	received
I-outcome	1306	1307	a
I-outcome	1308	1319	transfusion
I-outcome	1320	1326	during
I-outcome	1327	1336	treatment
O	1337	1341	were
B-iv-bin-percent	1342	1343	6
I-iv-bin-percent	1343	1344	%
O	1345	1346	(
O	1346	1348	95
O	1348	1349	%
O	1350	1352	CI
O	1352	1353	,
O	1354	1355	0
O	1355	1356	-
O	1356	1358	11
O	1358	1359	%
O	1359	1360	)
O	1361	1364	for
O	1365	1376	darbepoetin
O	1377	1381	alfa
O	1382	1385	and
B-cv-bin-percent	1386	1388	16
I-cv-bin-percent	1388	1389	%
O	1390	1391	(
O	1391	1393	95
O	1393	1394	%
O	1395	1397	CI
O	1397	1398	,
O	1399	1400	7
O	1400	1401	%
O	1401	1402	-
O	1402	1404	25
O	1404	1405	%
O	1405	1406	)
O	1407	1410	for
O	1411	1418	epoetin
O	1419	1423	alfa
O	1423	1424	.

O	1425	1429	Most
O	1430	1438	patients
O	1439	1440	(
B-iv-bin-abs	1440	1442	67
O	1443	1451	patients
O	1452	1461	receiving
O	1462	1473	darbepoetin
O	1474	1478	alfa
O	1479	1480	[
B-iv-bin-percent	1480	1482	93
I-iv-bin-percent	1482	1483	%
O	1483	1484	]
O	1484	1485	;
B-cv-bin-abs	1486	1488	61
O	1489	1497	patients
O	1498	1507	receiving
O	1508	1515	epoetin
O	1516	1520	alfa
O	1521	1522	[
B-cv-bin-percent	1522	1524	90
I-cv-bin-percent	1524	1525	%
O	1525	1526	]
O	1526	1527	)
B-outcome	1528	1537	exhibited
I-outcome	1538	1539	a
I-outcome	1540	1550	clinically
I-outcome	1551	1561	meaningful
I-outcome	1562	1568	target
I-outcome	1569	1571	Hb
I-outcome	1572	1577	level
O	1578	1579	>
O	1580	1582	or
O	1583	1584	=
O	1585	1587	11
O	1588	1589	g
O	1589	1590	/
O	1590	1592	dL
O	1592	1593	.

O	1594	1596	No
O	1597	1608	differences
O	1609	1611	in
B-outcome	1612	1618	safety
O	1619	1623	were
O	1624	1632	observed
O	1632	1633	.

O	1634	1639	These
O	1640	1647	results
O	1648	1655	suggest
O	1656	1660	that
O	1660	1661	,
O	1662	1664	in
O	1665	1673	patients
O	1674	1678	with
O	1679	1685	breast
O	1686	1692	cancer
O	1692	1693	,
O	1694	1705	darbepoetin
O	1706	1710	alfa
O	1711	1714	200
O	1715	1721	microg
O	1722	1727	every
O	1728	1729	2
O	1730	1735	weeks
O	1736	1739	and
O	1740	1747	epoetin
O	1748	1752	alfa
O	1753	1755	40
O	1755	1756	,
O	1756	1759	000
O	1760	1761	U
O	1762	1768	weekly
O	1769	1775	result
O	1776	1778	in
O	1779	1789	comparable
O	1790	1798	clinical
O	1799	1807	outcomes
O	1808	1811	for
O	1812	1815	the
O	1816	1825	treatment
O	1826	1828	of
O	1829	1841	chemotherapy
O	1841	1842	-
O	1842	1849	induced
O	1850	1856	anemia
O	1856	1857	.
